Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005227235
Tue, 30.07.2024
Biotest AG
PRESS RELEASE
Biotest increases sales in the first half of 2024 by 35% to € 372 million
EBIT increased to € 78.4 million
FDA approval of Yimmugo® received in June 2024
FDA certification of the BNL production facility in Dreieich
Strategic distribution agreement with Kedrion is expected to generate revenues of more than
$1 billion for [ … ]
Mon, 01.07.2024
Biotest AG
PRESS RELEASE
Biotest prepares launch of its immunoglobulin Yimmugo in the USA, establishing a framework for a strategic billion-dollar distribution agreement with Kedrion
Production of U.S. launch quantities of Yimmugo® has commenced following BLA approval
Biotest will start deliveries to the U.S. in Q4 2024 for the planned launch in Q1 [ … ]
Mon, 24.06.2024
Biotest AG
PRESS RELEASE
Biotest's sustainability campaign GoFuture part of the new documentary "Future Seeds"
Documentary shows sustainable projects from around the world and the eco-art mural "Linfa" on the Biotest campus
Film addresses socially relevant topic of eco-anxiety among young people
Now available on Prime Video in twelve countri [ … ]
Mon, 17.06.2024
Biotest AG
PRESS RELEASE
Milestone for Biotest: US approval for innovative immunoglobulin Yimmugo
FDA approval secures significant future sales and earnings growth through entry into the world's largest market
Manufactured at Biotest's state-of-the-art, FDA-certified “Next Level” facility in Germany
Dreieich, Germany, June 17, 2024. Biotest A [ … ]
Tue, 07.05.2024
Biotest AG
PRESS RELEASE
Biotest AG: Annual General Meeting approves dividend distribution
Distribution of EUR 0.04 per preference share for each of the years 2023 and 2022
Broad majority in the vote in line with the management's proposals
Dreieich, 07 May 2024. At the Annual General Meeting on May 7, 2024, the shareholders of Biotest AG resolved to di [ … ]
Tue, 07.05.2024
Biotest AG
PRESS RELEASE
Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024
Product sales increased by 17.7% to Euro 138.0 million
EBIT increased to Euro 52.8 million
Successful completion Fibrinogen study
Dreieich, 07 May 2024. The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 202 [ … ]
Fri, 19.04.2024
Biotest AG
PRESS RELEASE
Biotest AG opens 12th plasma collection centre in Germany
38 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 19 April 2024: Biotest has officially opened its 12th plasma collection centre in Germany in Wuppertal.
In future, plasma donors will be able to donate plasma five days a week [ … ]
Thu, 28.03.2024
Biotest AG
PRESS RELEASE
Biotest AG increased sales by 32% in the financial year 2023
EBIT forecast achieved with EBIT of € 143 million
Yimmugo marketing authorization application submitted to the US FDA
Phase III study with fibrinogen successful
Dreieich, 28 March 2024. In the financial year 2023, the Biotest Group generated revenue of € 684.6 mil [ … ]
Thu, 28.03.2024
Biotest AG
PRESS RELEASE
Biotest AG increased sales by 32% in the financial year 2023
EBIT forecast achieved with EBIT of € 143 million
Yimmugo marketing authorization application submitted to the US FDA
Phase III study with fibrinogen successful
Dreieich, 28 March 2024. In the financial year 2023, the Biotest Group generated revenue of € 684.6 mil [ … ]
Thu, 29.02.2024
Biotest AG
PRESS RELEASE
Biotest achieves EBIT forecast for 2023
Proposal to this year's Annual General Meeting that preference dividend for the 2023 financial year and the subsequent payment of the preference dividend for the 2022 financial year to be distributed to the preference shareholders.
Dreieich, 29 February 2024: According to p [ … ]